SAPIENS INTERNATIONAL Reports 8.2% Increase in Revenue for Q2 2023

August 7, 2023

☀️Earnings Overview

For the quarter ending June 30 2023, SAPIENS INTERNATIONAL ($NASDAQ:SPNS) saw total revenue of USD 128.3 million, representing an 8.2% increase from the same quarter in 2022. Net income for the quarter totaled USD 15.4 million, a 29.3% increase year over year.


GoodWhale conducted an analysis on SAPIENS INTERNATIONAL‘s wellbeing and the result was remarkable. According to the Star Chart, SAPIENS INTERNATIONAL is quite strong in asset, dividend, growth, and profitability. Furthermore, its overall health score is a perfect 10 out of 10. This means that the company has healthy cashflows and is able to sustain future operations in times of crisis. SAPIENS INTERNATIONAL has been classified as ‘gorilla’, which means that it has achieved stable and high revenue or earning growth due to its strong competitive advantage. Given its strong position and reliable performance, investors who are looking for stability and future growth could be very interested in investing in a company like SAPIENS INTERNATIONAL. Those who are looking for a long-term investment would definitely find this company to be worth consideration. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Sapiens International. More…

    Total Revenues Net Income Net Margin
    491.48 56.36 11.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Sapiens International. More…

    Operations Investing Financing
    55.63 -64.11 -46.32
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Sapiens International. More…

    Total Assets Total Liabilities Book Value Per Share
    653.04 234.36 7.26
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Sapiens International are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    11.7% 18.5% 14.7%
    FCF Margin ROE ROA
    9.4% 11.2% 6.9%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    Its main competitors are BlueRush Inc, IRESS Ltd, and Nika DD. Sapiens has a strong market position, with a large customer base and a wide range of products.

    However, its competitors are also well-established and offer similar solutions.

    – BlueRush Inc ($TSXV:BTV)

    BlueRush Inc. is a publicly traded company with a market capitalization of $5.97 million as of 2022. The company has a return on equity of 111.72%. BlueRush Inc. is a provider of digital marketing and technology solutions. The company offers a suite of services including website design and development, search engine optimization, social media marketing, and email marketing.

    – IRESS Ltd ($ASX:IRE)

    The company has a market cap of 1.81B as of 2022. The company’s ROE is 11.28%. The company is a provider of digital marketing services.


    SAPIENS INTERNATIONAL has reported a positive financial quarter ending June 30 2023, with total revenue of USD 128.3 million and a net income of USD 15.4 million, both showing an impressive year-over-year growth of 8.2% and 29.3%, respectively. This has been reflected in the stock price, which has moved up on the same day. This strong performance indicates that SAPIENS INTERNATIONAL is a solid investment opportunity and shows a positive outlook for the future. Investors should consider investing in SAPIENS INTERNATIONAL, as its financials are strong and the potential for future growth is promising.

    Recent Posts

    Leave a Comment